Published within
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Generics maker Cipla is trying to cut a deal to supply South African mining firm Anglo American with HIV drugs. Employer provision of HIV medicine is gaining popularity in South Africa, and last year's court case created the opportunity for the government to license generic versions of patented drugs. However, it has so far been reluctant to use this power.
Published By Datamonitor
|
20 Aug 2002 |
|
CommentWire
|
While the WTO has not yet made a breakthrough on the issue of patent-free HIV drugs for developing economies, something must be done to alleviate the human and economic cost of the HIV epidemic. Western pharma companies will inevitably lose out - the only question is how well their profit maintenance strategies can cushion the blow.
Published By Datamonitor
|
22 Oct 2002 |
|
CommentWire
|
Pfizer's share price has surged on news that the company has successfully defended two key Lipitor patents, deferring the threat of generic competition until 2011. This will enable Pfizer to proceed with plans to switch Lipitor patients to its controversial phase III torcetrapib and atorvastatin combination product before Lipitor is affected by generic competition, safeguarding its revenue stream.
Published By Datamonitor
|
20 Dec 2005 |
|
CommentWire
|
US-based Merck and India's biggest pharmaceutical company Ranbaxy have entered into an agreement to develop antibacterial and antifungal drugs. The deal highlights the trend of big pharmaceutical companies turning to India and China for R&D. As well as allowing Merck to develop its infectious disease portfolio, the agreement should provide valuable synergies for both companies.
Published By Datamonitor
|
13 May 2008 |
|
Expert View
|
One of Barack Obama's key goals as president is to reduce healthcare costs, particularly those related to prescription medications, by increasing the importation of generic drugs. However, the majority of these, or their ingredients, are manufactured in China, and to build confidence in such products, which are often considered unsafe, the FDA will require updated IT systems and solutions.
Published By Datamonitor
|
17 Nov 2008 |
|
CommentWire
|
A new discussion paper from the Indian government has proposed compulsory licensing for patented drugs. While this is unlikely to have a sizable impact given India's track record with patent rejections, the paper also mentions possible profit controls for drugs. These would certainly be more painful and would threaten branded pharmaceutical companies' expansion strategies into emerging markets.
Published By Datamonitor
|
02 Sep 2010 |
|
CommentWire
|
The dispute between India and the European Union over recent seizures of Indian-made generics by a number of European countries has been settled before World Trade Organization action. However, Indian drug producers are growing increasingly concerned about the Anti-Counterfeiting Trade Agreement, and that it may allow seizures to become more commonplace.
Published By Datamonitor
|
12 Oct 2010 |
|
CommentWire
|
AusBiotech 2010, the annual conference of the Australian biotechnology industry, has sought to educate attendees about recent trends in the global pharmaceutical market, and how they can best take advantage of current conditions. This includes exploring opportunities with regional Asia Pacific neighbors, with a potential collaboration between Australia and India one of the key talking points.
Published By Datamonitor
|
25 Oct 2010 |
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.